Significant decrease in serum very low density lipoproteins and low density lipoproteins was observed after Bay g 5421 trial (300 mg/day for 6 weeks) in 14 hyperlipidemic patients. Although no significant changes were demonstrated in serum fractions of bile acids, the altera tion in the patterns of fecal bacterial flora including the increase in obligate anaerobes was observed after the trial and this was accompanied by the increase in fecal fat excretion. Thus, the possible change in the intestinal bile acid metabolism with the altered flora may lead to an increased catabolism of cholesterol and to the reduction of serum low density lipoproteins. The meteorism developed in several patients but its etiology was shown to be independent of the patterns of the pre-trial bacterial flora and diet composition. -glucoside-hydrolase in hibitor; serum lipoproteins; fecal flora; bile acids; meteorism A new glucoside-hydrolase inhibitor (Bay g 5421, Bayer AG, West Germany), when taken orally, is known to delay the intestinal absorption of starch and sucrose by inhibiting maltase and sucrase activities (Schmidt et al. 1977; Puls et al. 1977) . Since this acarbose diminishes the postprandial increase of blood glucose, it may be of value in the management of diabetic patients (Walton et al. 1979; Sachse and Willms 1979) . Our previous study also revealed that the administration of the drug. decreases the postprandial insulin secretion in the normal and hyperinsulinemic subjects (Maruhama and Goto 1980) . The administration of Bay g 5421 (300 mg/ day for 4 weeks) to hyperlipidemic patients complicated with hyperinsulinemia significantly reduced the serum levels of both triglyceride (TG) and cholesterol (Chol) while their body weight remained unchanged (Maruhama and Goto 1980) . This lipid lowering effect of Bay g 5421 could partially be accounted for by the daily inhibition of the otherwise accelerated postprandial insulin secretion which increases hepatic production and release of TG-rich lipoproteins, very low density lipoproteins (VLDL). However, the significant decrease in serum Chol after the drug administration may not solely be attributed to the reduction of VLDL. The metabolism of Chol-rich lipoproteins, low density lipoproteins (LDL), might have also been affected by Bay g 5421. The possibility thus remains that the drug has a direct effect on the metabolism of lipids including Chol in the intestine. In our previous trial, a few patients complained of gas symptoms (abdominal distention and flatulence), which in some instance were intolerable. The increase in gas production was shown to be due to the interaction between bacterial flora and unabsorbed carbohydrate in the colon as indicated by a serial breath hydrogen analysis after the meal with Bay g 5421 (Caspary 1978; Maruhama and Goto 1980) . However, it remains unclear why the symptoms occur in certain subjects.
In the present study, changes in serum lipoproteins and bile acids as well as in fecal fat and bacteria were investigated in hyperlipidemic patients after Bay g 5421 administration in order to see effects of the drug on lipid metabolism in the circulating blood and intestine. The patterns of dietary intake and bacterial flora were also analysed in relation to the gas symptoms after the drug administration. 
SUBJECTS AND METHODS

General procedures
Blood analyses
Venous blood samples were obtained after an overnight fast on the day of the start of Bay g 5421 administration and after the trial of 6 weeks. Blood glucose (Huggett and Nixon 1957) and serum TG (Fletcher 1968) and Chol (Zlatkis and Zak 1969) were measured . Serum lipoproteins were analysed by an agarose-gel electrophoresis (Noble 1968) . Serum lipoprotein fractions were separated with a preparative ultracentrifuge (Hitachi Model 55 P-7 with a titanium angle roter RP 55T) according to the the method of Havel et al . (1955) modified by Nikkila and Hormilla (1978) , and TG (Fletcher 1968) and Chol (Zlatkis and Zak 1969) were measured in each lipoprotein fraction.
Serum bile acids were measured enzyme-fluorometrically based on the method of Mashige et al . (1976) after the fractionation by hydrophobic ion-exchange chromatography on piperidinohydroxypropyl Sephadex LH -20 (Kimura et al. 1979 
Fecal fat
Fecal fat excretion was measured on the day prior to the start of Bay g 5421 administra tion and on the final day of the trial in 14 patients.
The total feces excreted during the day was collected and homogenized in a polyvinyl bag, and then a portion of the sample was taken for analysis of total fat (Van de Kamer 1949).
Fecal bacteria A portion of the fecal sample was used for the culture, identification and counting of bacterial flora (Mitsuoka 1971; Tamura et al. 1978) . In these procedures 13 selective culture mediums were used for identification and the mean colony counts from plates containing known numbers of microorganisms were calculated.
The numbers of specific microorganisms were expressed as the logarithm to the base 10 of the number of viable microorganisms per gram of feces. Fecal flora was analysed on the day prior to the start of the trial and on the final day of the trial in 14 patients.
Breath hydrogen
Breath hydrogen, which is derived from the blood and originally produced during the degradation of carbohydrate by the bacteria in the colon, is known to increase in proportion to the amount of carbohydrate reaching the colon. Thus, the analysis of breath hydrogen after meal is useful in studying dynamics of carbohydrate digestion and absorption in the gut (Levitt 1969; Levitt and Donaldson 1970) . In the present study, this analysis was applied for an objective estimate of meteorism after Bay g 5421 administration.
Approximately 50 ml of breath was collected by the end-expiratory sampling technique using the apparatus of Metz et al. (1976) and exact 1 ml of the sample was analysed for hydrogen content by a Yanaco Type G 1800-T gaschromatograph (Yanagimoto Co., Kyoto) with argon as a carrier gas. An internal standard of hydrogen (9 ppm in nitrogen) was referred in each analysis.
Five to six serial analyses were performed at 10 min intervals between 3 and 4 hr after the regular breakfast with 100 mg of Bay g 5421 1 week as well as 6 weeks after the start of the trial.
Diet analysis
Fourteen patients were examined for dietary intake during the sequential 3 days prior to the start of the trial according to the quantitative diet record method as described pre viously (Maruhama et al. 1977 ). The daily nutrient intake was calculated in each patient by an established dietitian based on Japanese Food Composition 
Serum bile acids
As shown in Table 2 , the administration of Bay g 5421 for 6 weeks produced no significant change in the free or conjugated bile acids, total bile acids, or the ratio of glycine-conjugated bile acids to taurine-conjugated bile acids. However, in guessing the possible change of bile acids in the intestine, some trend to increase observed in serum free bile acids and the ratio of glycine-conjugated bile acids to taruine-conjugated bile acids might be of value .
Other parameters in serum
Blood glucose, the liver function tests or serum proteins , uric acid or urea nitrogen showed no change during Bay g 5421 treatment.
Fecal fat
As shown in Table  3 
Fecal bacterial flora
The administration of Bay g 5421 for 6 weeks produced a significant increase in lactobacillus and bifidobacterium, and a significant decrease in enterobacteriaceae, bacteroidaceae and lecithinase positive clostridium, as shown in Table 4 . Although no significant change was observed in the numbers of total bacteria, there was a trend to increase in the numbers of fecal obligate anaerobes after the trial.
Analysis of gas symptoms
Two patients, who dropped out of this study, complained of intolerable increase in the abdominal distention and flatulence within a few days after the start of the trial.
Four patients also complained of meteorism from the 1st day to the end of the trial showing a fluctuation.
The symptoms in these patients were mild or moderate and not intolerable.
A plain abdominal x-ray film taken on the 2nd day after the start of the trial revealed gas accumulation mainly in the colon with enlarged hepatic and splenic flextures (Patient C.K. in Table 5 ). A typical gaschromatographic chart of breath hydrogen obtained in Patient C.K. 1 week after the start of the trial is shown in Fig. 1 . The average breath hydrogen concentra tions following the breakfast with 100 mg of Bay g 5421 1 week after the start of the trial increased to 81-145 ppm as shown in Table 5 , but there were no changes in the breath hydrogen concentration after the trial for 6 weeks. The breath hydrogen in the patients without gas symptoms was less than a half of that in the and 4 hr after breakfast with 100 mg of Bay g 5421 in each patient . In 3 subjects without gas symptoms, breath hydrogen during the corresponding postprandial periods ranged between 25 and 59 ppm . Treat ment with Bay g 5421 was not discontinued up to the 6th week in the above 4 patients. patients with gas symptoms (see footnote for Table 5 ). The pre-trial fecal bac terial flora in the patients in whom the gas symptoms soon developed did not differ significantly from that in the patients who did not complain of the symptoms as shown in Table 6 . Daily dietary intake in the patients with and without the gas symptoms is shown in Table 7 . There were no significant differences in the daily caloric consumption as well as in each nutrient intake between the patients with and without gas symptoms. 
DISCUSSION
The present study confirms our previous report that serum TG and Chol decrease significantly by Bay g 5421 treatment whereas weight reduction can hardly be achieved by this treatment (Maruhama and Goto 1980) . In addition, the decrease in serum TG and Chol was shown to be due to the decrease in the respective carriers, VLDL and LDL. The VLDL reduction after the trial might be accounted for by the reduction of the insulin-mediated hepatic VLDL production as suggested previously (Maruhama and Goto 1980) . However, the mechanism through which LDL is reduced seems to be complicated. There have been only a few therapeutic tools that could lower both VLDL and LDL simultaneously. Para-aminosalicylic acid and dietary fiber are known to ameliorate the elevations of both VLDL and LDL. The hepatic as well as intestinal effects have been postulated for p-aminosalicylic acid (Barter et al. 1974; Kuo et al. 1976; Goldberg et al. 1978) . The effect on the intestine including bacterial flora and bile acids might be dominant for dietary fiber (Truswell and Kay 1976; Durrington et al. 1976 ; Morris et al. 1977 ). The trial with Bay g 5421 for 6 weeks produced an increase in fecal fat content and fecal weight. Although the total numbers of fecal bacteria was not influenced significantly, the flora patterns were shown to alter considerably after Bay g 5421; an increase in lactobacillus and bifidobacterium and a decrease in entero bacteriaceae, bacteroidaceae and clostridium. These changes are strikingly similar to those reported by Drasar et al. (1976) after a high fiber diet in man. Fuchs et al. (1976) also observed that the fecal anaerobes increased significantly after a fiber-rich diet accompanied by an increased fecal weight. The changes in such fecal flora seem to accelerate bile acid deconjugation resulting in an increase in bile acid excretion into the feces and therefore bile acid turnover (Gorbach and Tabaqchali 1969; Neale et al. 1972) . Under these conditions the fecal fat excretion is known to increase (Neale et al. 1972) , as shown in this study. A mechanical effect of the increased passage of the intestinal content after Bay g 5421, as is in duced after a high fiber diet, nay also accelerate the excretion of fat and bile acids into the feces (Heaton 1972 ). We did not estimate fecal bile acids in this study. However, the slight trend in serum free bile acids and the ratio of glycine-conjugated bile acids to taurine-conjugated bile acids to increase may suggest the bile acid deconjugation by the increased obligate anaerobes and the accelerated fecal bile acid excretion (Heaton 1972 ). Although we only obtained the minor indirect findings , the possible intestinal changes after Bay g 5421 administration seem to be near to those after the fiber-supplemented diet. Serum LDL thus seems to decrease as the fecal excretion of bile acids increases and therefore the hepatic cholesterol degradation increases.
The meteorism, the accumulation of gas in the colon, that was demonstrated by breath hydrogen and x-ray film is etiologically not simple. It is noteworthy that the gas symptoms developed not in all but in certain patients. The symptoms which occur soon after the drug administration are apparently not due to the chronic change induced by the drug. In the occurrence of the symptoms , the pre-trial parameters of the individual patients seem to be important. There were, however, no differences in the pre-trial data on the patterns or total numbers of fecal flora between the patients with and without the gas symptoms. There were no differences between the patients in the intake of the nutrients including carbohydrate which also relates to colonic gas production. Thus, the differences in the motility of the gastrointestinal tract, in the sensitivity to Bay g 5421 or in
other factors seem to accelerate the gas production. At present, the reduction in the daily dosage or the intermittent administration of Bay g 5421 seems to be needed in the maintenance of the drug treatment in such patients.
